TrialBlood2016

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.

Andreas Viardot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.